These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28781242)

  • 1. Outcome of percutaneous coronary intervention with the Absorb bioresorbable scaffold: data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Grimfjärd P; James S; Persson J; Angerås O; Koul S; Omerovic E; Varenhorst C; Lagerqvist B; Erlinge D
    EuroIntervention; 2017 Dec; 13(11):1303-1310. PubMed ID: 28781242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedural and Long-Term Outcomes of Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions: The BONITO Registry (Bioresorbable Scaffolds Versus Drug-Eluting Stents in Chronic Total Occlusions).
    Azzalini L; Giustino G; Ojeda S; Serra A; La Manna A; Ly HQ; Bellini B; Benincasa S; Chavarría J; Gheorghe LL; Longo G; Miccichè E; D'Agosta G; Picard F; Pan M; Tamburino C; Latib A; Carlino M; Chieffo A; Colombo A
    Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27765802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction).
    Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stent thrombosis in new-generation drug-eluting stents in patients with STEMI undergoing primary PCI: a report from SCAAR.
    Sarno G; Lagerqvist B; Nilsson J; Frobert O; Hambraeus K; Varenhorst C; Jensen UJ; Tödt T; Götberg M; James SK
    J Am Coll Cardiol; 2014 Jul; 64(1):16-24. PubMed ID: 24998123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry.
    Wiebe J; Hoppmann P; Colleran R; Kufner S; Valeskini M; Cassese S; Schneider S; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    JACC Cardiovasc Interv; 2017 Jun; 10(12):1222-1229. PubMed ID: 28641842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics, Predictors, and Mechanisms of Thrombosis in Coronary Bioresorbable Scaffolds: Differences Between Early and Late Events.
    Gori T; Weissner M; Gönner S; Wendling F; Ullrich H; Ellis S; Anadol R; Polimeni A; Münzel T
    JACC Cardiovasc Interv; 2017 Dec; 10(23):2363-2371. PubMed ID: 29216999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
    Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
    Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates and outcomes of late and very late drug-eluting stent thrombosis: results from DESERT (International Drug-Eluting Stent Event Registry of Thrombosis).
    Waksman R; Kirtane AJ; Torguson R; Cohen DJ; Ryan T; Räber L; Applegate R; Waxman S; Gordon P; Kaneshige K; Leon MB;
    JACC Cardiovasc Interv; 2014 Oct; 7(10):1093-102. PubMed ID: 25240540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence, Clinical Presentation, and Predictors of Clinical Restenosis in Coronary Bioresorbable Scaffolds.
    Polimeni A; Weissner M; Schochlow K; Ullrich H; Indolfi C; Dijkstra J; Anadol R; Münzel T; Gori T
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1819-1827. PubMed ID: 28935073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life clinical outcomes with everolimus eluting platinum chromium stent with an abluminal biodegradable polymer in patients from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Sarno G; Lagerqvist B; Olivecrona G; Varenhorst C; Danielewicz M; Hambraeus K; Lindholm D; Råmunddal T; Witt N; James S
    Catheter Cardiovasc Interv; 2017 Nov; 90(6):881-887. PubMed ID: 28544146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparable clinical safety and efficacy of biodegradable versus durable polymer paclitaxel eluting stents despite shorter dual antiplatelet therapy: insights from a multicenter, propensity score-matched registry.
    Buszman PP; Orlik B; Trela B; Milewski K; Kozlowski M; Pruski M; Drzewiecki J; Peppas A; Granada JF; Kaluza GL; Buszman PE
    Catheter Cardiovasc Interv; 2013 Sep; 82(3):E155-62. PubMed ID: 23109067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
    Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
    JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proximal coronary artery intervention: stent thrombosis, restenosis and death.
    Calais F; Lagerqvist B; Leppert J; James SK; Fröbert O
    Int J Cardiol; 2013 Dec; 170(2):227-32. PubMed ID: 24211065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Borderline trend towards long-term mortality benefit from drug eluting stents implantation in ST-elevation myocardial infarction patients in Poland-data from NRDES registry.
    Siudak Z; Dziewierz A; Rakowski T; Żmudka K; Legutko J; Bartuś S; Dragan J; Zasada W; Tokarek T; Kułaga T; Partyka Ł; Dudek D
    Catheter Cardiovasc Interv; 2014 Feb; 83(3):436-42. PubMed ID: 24038740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained risk of stent thrombosis and restenosis in first generation drug-eluting Stents after One Decade of Follow-up: A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
    Völz S; Angerås O; Odenstedt J; Ioanes D; Haraldsson I; Dworeck C; Redfors B; Råmunddal T; Albertsson P; Petursson P; Omerovic E
    Catheter Cardiovasc Interv; 2018 Nov; 92(6):E403-E409. PubMed ID: 29745465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A propensity score-matched comparison of biodegradable polymer vs second-generation durable polymer drug-eluting stents in a real-world population.
    Zhao YJ; Teng M; Khoo AL; Ananthakrishna R; Yeo TC; Lim BP; Loh JP; Chan MY
    Cardiovasc Ther; 2018 Apr; 36(2):. PubMed ID: 29316284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.